Term
|
Definition
| 16 H, 9 N; moderate to severe illness; all age groups; humans and other animals |
|
|
Term
|
Definition
| milder epidemics; humans only; primarily affects children |
|
|
Term
|
Definition
| rarely reported in humans; no epidemics or significant disease |
|
|
Term
| gradual mutation; may result in epidemic, widespread illness |
|
Definition
|
|
Term
| more precipitous genetic recombo of 2 different strains, occurs at unpredictable intervals; pandemic may result |
|
Definition
|
|
Term
| new influenza virus; animals as reservoir and infect a variety of hosts; efficiently transmitted between humans |
|
Definition
|
|
Term
| infection is maintained in population |
|
Definition
|
|
Term
| new cases of disease exceeding what is expected |
|
Definition
|
|
Term
| epidemic that is spreading through populations across large region/worldwide; non-stable |
|
Definition
|
|
Term
| Primary spread of influenza |
|
Definition
| inhale droplets (sneezing, coughing, talking); up to 6 feet away |
|
|
Term
| Minor spread of influenza |
|
Definition
| direct contact; indirect contact (possibly)- stethoscope, computer keyboards, phones |
|
|
Term
| Respiratory transmission of virus --> |
|
Definition
| replication in respiratory epithelium with subsequent destruction of cells |
|
|
Term
| Viral shedding in respiratory secretions |
|
Definition
|
|
Term
|
Definition
| up to 5-7 days after symptoms begin (longer in children) |
|
|
Term
|
Definition
| due to body's immune reaction to virus |
|
|
Term
| Time from infection to symptoms |
|
Definition
|
|
Term
| Influenza symptoms (abrupt onset!) |
|
Definition
| fever, cough, sore throat, shortness of breath, myalgia, headache, malaise, rhinitis or stuffy nose, vomiting and diarrhea |
|
|
Term
|
Definition
|
|
Term
| who are we most worried about for influenza? |
|
Definition
| children <5, esp <2 years; pregnant, elderly; pulmonary, neurological conditions; heart disease, blood, metabolic disorders; weakened immune system; persons <19 years on long term aspirin therapy |
|
|
Term
|
Definition
| put in 4 different strains into vaccine |
|
|
Term
|
Definition
| put in 3 strains into vaccine |
|
|
Term
| IM Flu Vaccines (Fluzone) |
|
Definition
| Single use syringes vials, multi-dose vials; 0.25 mL IM 6-35 months; 0.5 mL IM greater than 35 months |
|
|
Term
| IM Flu Vaccine SEs (Fluzone) |
|
Definition
| injection site reaction; low grade fever; aches |
|
|
Term
|
Definition
| Quad strength inactivated flu vaccine; for 65 years and older option |
|
|
Term
|
Definition
|
|
Term
|
Definition
| Intranasal single-use spray; live attenuated cold-adapted virus; side effects include runny or stuffy nose, headache, sore throat, cough |
|
|
Term
|
Definition
| 0.1 mL in 1 nostril, then 0.1 mL in other |
|
|
Term
|
Definition
| 0.1 mL; 18-64 years of age |
|
|
Term
| 2 A strains and 2 B strains; |
|
Definition
| Quadrivalent (QIV) vaccines |
|
|
Term
|
Definition
| Approved in Jan 2013; 18-49 years; Trivalent, egg-free; shorter shelf life (16 weeks from production) |
|
|
Term
|
Definition
| cell-culture based vaccine; trivalent; does not contain egg proteins; assess egg allergy history |
|
|
Term
|
Definition
|
|
Term
|
Definition
| cell culture and recombinant vaccines |
|
|
Term
|
Definition
| preservative; 50% ethylmercury (not methylmercury)-- actively excreted in gut |
|
|
Term
|
Definition
| influenza A and B; Adults: Prophylaxis 75 mg daily; treatment 75 mg BID |
|
|
Term
|
Definition
| Influenza A and B; prophylaxis >4 yrs 2 inhalations daily; treatment >6 years 2 inhalations BID |
|
|
Term
|
Definition
| cough, bronchospasm, sinusitis, dizziness |
|
|
Term
|
Definition
| Txt: 5 days, longer for severely ill can be considered Prophylaxis: 7 days after exposure. |
|
|
